Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Chronic Hepatitis C Virus Infection
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Study to assess the antiviral efficacy, pharmacokinetics and tolerability of BILN 2061 ZW in
a polyethyleneglycol 400 (PEG 400: ethanol) drinking solution given for two days bid in
patients with chronic Hepatitis C Virus (HCV) infection.